BPC-157 Half Life — What Research Shows

One of the frequently asked questions about BPC-157 is the duration of its activity in the body. The simple answer is that there is no conducted study showing the half-life of BPC-157 pharmacokinetics in any type of organism, so what we have instead is some hints from the dosing intervals used in animal experiments, general information about short peptide clearance, and claims about the specificity of BPC-157's stability in gastric juice. We present the collected information in a clear manner.

BPC-157 Half Life - What Is Actually Published

The PK Data Gap for This Peptide

In order to conduct a pharmacokinetic half-life investigation, blood or tissue levels of the substance must be taken at various time intervals after its administration before observing the patter of decrease to derive elimination constant. No study has been published on BPC-157 in scientific journals up to October 2026 demonstrating the use of time-concentration curve. The original work of Sikiric and his associates as reported in their review published in 2018 (PMID 29879879) discusses functional outcomes such as healing rates and tendon strength without exploring the level of concentration in the blood. So the available effectiveness information is based on studies done on animals, while pharmacokinetics parameters are not available for this substance.

Indirect Evidence From Dosing Frequency in Studies

Authors that published the studies on BPC-157 usually recommend usage of the peptide not more than once per day. The table below provides information on the frequency of injections based on key studies.

Using a dose for once-daily dosing may have been more convenient in regards to performing an animal study rather than optimizing pharmacokinetics. No clear rationale was provided for using a half-life to decide whether dosing should be done once versus twice a day. Also, no study has conducted comparisons between dosing frequencies to analyze their potential effect on the results.

What Half Life Means for a Peptide

Proteolytic Degradation in Circulation

The peptides circulating in the bloodstream are quickly broken down by enzymatic processes. Proteases and peptidases located in the plasma, the liver, and the kidneys hydrolyze peptide bonds to produce smaller and biologically inactive fragments. The half-lives of all regular peptides ranging from 5 to 15 amino acids are measured in minutes rather than hours. BPC-157 is a peptide composed of 15 amino acids that originates from a bigger protein found in the gastric juice (the body protection compound). BPC-157 remains unchanged by post-translational modifications such as PEGylation and lipidation, which extend its time in the circulatory system.

Route of Administration Changes the Timeline

Administering the medicine has a significant impact on its effectiveness. For instance, an intraperitoneal or subcutaneous injection will put peptide circulation into action fairly quickly, allowing for the start of clearance immediately. On the other hand, oral regimens undergo various processes before entering systemic blood, including surviving the stomach acid and proteases, traveling through the gut epithelium, and entering the portal circulation system. When it comes to the majority of peptide compounds, oral bioavailability is often minimal due to the effect of gastric and intestinal enzymes on the samples. BPC-157 stands out among all other peptide compounds as it has been shown to have some active effects even when taken orally; however, this cannot be equated with calculating the effect after taking this compound orally, and determining its true biological half-life.

Estimates From Related Peptide Data

Short Peptides Generally Clear in Minutes to Hours

We can consider similar peptides to gain an approximate idea of the function. Oxytocin, which is made up of 9 amino acids and has a plasma half-life of approximately 3 to 5 minutes. GnRH (gonadotropin-releasing hormone) is made up of 10 amino acids and has a plasma half-life of 2 to 4 minutes. Large peptides and small proteins usually have slightly longer half-lives. Thymosin beta-4 (43 amino acids in total) has a half-life of approximately 2 hours. Insulin (51 amino acids in total) has a half-life of about 5 to 6 minutes, although its binding to receptors allows for longer biological activity. BPC-157 (consisting of 15 amino acids) falls into the category of small peptides and without modifying its structure we could see that the half-life could either be in single digits or possibly reach an hour.

BPC-157 Stability Claims and Their Basis

The uniqueness of BPC-157 in the literature is related to its resistance and stability in gastric juice. It is said to possess better capabilities to resist denaturation from acid and pepsin than similar peptides due to its origin, which comes from a protein produced in the stomach. This trait has been highlighted in multiple works by Sikiric and others. However, being stable in regard to gastric juice (resistance to acid denaturation) varies from having a stable plasma half-life (being resistant to enzymatic degradation in the bloodstream). In other words, it is still possible for a peptide to have gastric stability and be eliminated from the blood through liver and kidney peptidases. So there are two different matters concerning stability.

Why This Matters for Study Design

Daily Dosing Was Chosen for Practical Reasons

In the published studies conducted on rats, it was found that dosing was done once daily. The logic behind using the once-daily protocol likely has to do with it being the most straightforward regimen to follow by researchers dealing with laboratory animals. Scheduling doses is commonly done every 24 or 48 hours in research studies conducted on rodents. In the Staresinic tendon study, Brcic muscle study, and the Sikiric review, which thoroughly summarized the findings of the other studies, it was found that both employed the same dosing frequency.

No Study Optimized Frequency Based on PK

This signifies an interesting gap. In the world of pharmaceutical development, dosing frequency is usually determined after phase I PK studies establish how fast a compound will be absorbed, distributed, metabolized, and eliminated. However, when it comes to BPC-157, that step has never been documented. This means that we just have the dosing frequency chosen for the sake of convenient practice and efficacy endpoints that happened to work at that frequency with laboratory rats. It is unknown whether there would be any differences if the drug was administered twice a day or continuously.

In addition, it is worth mentioning that there exist some online communities that suggest that BPC-157 be administered subcutaneously twice a day. The reason behind this suggestion may be the assumption that the short peptide may be eliminated quite quickly and that administering the daily dose in two applications may help maintaining the blood concentration. However, despite the fact that the reasoning appears fairly sound overall, it is nevertheless not substantiated by any available studies on the subject of BPC-157 in particular.